HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Clinical trials for HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop High-Risk breast cancer from coming back
Disease control Recruiting nowThis phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Texts and smart gadget aim to boost cancer pill adherence
Disease control Recruiting nowThis study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for Hard-to-Treat breast cancer subtype
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a certain type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a specific ge…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New smart chemo targets tumors, spares healthy tissue
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for seniors with breast cancer: drug combo trial targets tough cases
Disease control Recruiting nowThis phase 2 trial is testing the safety of abemaciclib (Verzenio) combined with hormone therapy in people aged 70 and older with hormone receptor-positive metastatic breast cancer that has worsened after prior treatment with a similar drug. The study will enroll 43 participants …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to wipe out HER2-Low breast cancer before surgery
Disease control Recruiting nowThis phase II trial is testing whether a targeted drug called trastuzumab deruxtecan (Enhertu), given alone or with anastrozole (Arimidex), can eliminate HER2-low, hormone receptor positive breast cancer before surgery. The study will enroll 88 people with early-stage breast canc…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New vaginal suppository aims to ease dryness for breast cancer patients
Symptom relief Recruiting nowThis study tests whether Revaree Plus, a hyaluronic acid vaginal suppository, can improve vaginal dryness in women with hormone-receptor-positive breast cancer. About 60 participants will use the suppository for 8 weeks. Researchers will measure changes in vaginal health using a …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE4 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Acupuncture may help black women avoid debilitating joint pain during breast cancer treatment
Symptom relief Recruiting nowThis study tests whether in-person acupuncture or virtual acupressure can prevent joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It focuses on Non-Hispanic Black women with early-stage breast cancer, who are more likely to stop treatment du…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Blood test may spot breast cancer resistance before It's too late
Knowledge-focused Recruiting nowThis study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Breast cancer and sleepless nights: new study investigates the link
Knowledge-focused Recruiting nowThis study looks at how sleep changes in women with early-stage breast cancer during treatment. Researchers will track sleep patterns and check for links to stress, social support, and living environment. About 100 participants will wear a sleep monitor and answer surveys before,…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC